Next Generation Sequencing

Next Generation Sequencing (NGS) is an innovative technology that has revolutionized oncology research. Specifically, with NGS technology researchers are able to quickly sequence all exons in a genome (Whole Exome Sequencing or WES) and utilize RNA sequencing (RNA-Seq) to discover novel RNA variants and quantify mRNA for differential gene expression analysis. Additionally, Digital RNA with pertUrbation of Genes sequencing (DRUG-seq) can be used to study an agent's effect on the transcriptome and investigate mechanisms of action and profiles of drug response and resistance, using limited starting material.

Champions Oncology now provides Next Generation Sequencing as an endpoint for in vivo and ex vivo studies. Tissue processing post-study completion at our US-based facilities provides fast turnaround times with reliable high-quality data analysis and visualization using Champions' innovative web application, Lumin.

As oncology experts, our team has deep scientific competencies to not only aid in the planning of your upcoming in vivo or ex vivo study, but to recommend NGS endpoint analyses that can help you discover endless insights with your therapeutic candidate from our highly characterized tumor bank.